Nebenwirkungen · Iclusig
Iclusig 5 mg hard capsules · Abschnitt 4.8 · PDF-Seite 57–58
HOS-128568 · Präparat HOS-096579
57 Patients with newly diagnosed Ph+ ALL (PhALLCON Study) Myelosuppression events were reported in 83 % of ponatinib-treated patients in PhALLCON. The most frequently reported adverse drug reactions were thrombocytopenia (47%), neutropenia (44%) and anaemia (44%). Events of hepatotoxicity occurred in 64 % of patients. Overall a higher incidence of myelosuppression associated with chemotherapy (febrile neutropenia, pyrexia, pneumonia and sepsis) as well as peripheral sensory neuropathy and stomatitis was observed as compared to the use of ponatinib alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-31T14:12:00Z · SHA-256 4867aa10684948b4c421d8ab4cf806af86df3e9279763348c485fe3b6e3627c4 · Passage 68f12e190db619b203f5adfb6745438e0e9fda7b6d2bbcdc9cd03e78dd819d49 · Zeichen 2677–3238 im Abschnitt